The fourth cohort of the CheckMate 040 trial enrolled patients with advanced HCC previously treated with Sorafenib and administered a nivolumab-ipilimumab (anti-PD-1 and anti-CTLA-4, respectively) combination. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.